Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Cardiac and vascular atrogin-1 mRNA expression is not associated with dexamethasone efficacy in the monocrotaline model of pulmonary hypertension.

Authors: Paffett, Michael L; Channell, Meghan M; Naik, Jay S; Lucas, Selita N; Campen, Matthew J

Published In Cardiovasc Toxicol, (2012 Sep)

Abstract: Atrophic signaling elements of the ubiquitin-proteasome system (UPS) are involved in skeletal muscle wasting as well as pressure overload models of heart failure. In our prior experiments, we demonstrated a transcriptional downregulation of atrophy-inducing vascular E3 ubiquitin ligases in a toxic model of pulmonary hypertension where pulmonary artery and right ventricle (RV) hypertrophy are evident. Given the numerous reports of glucocorticoid activation of the UPS and the negative regulator of muscle mass, myostatin, we investigated the efficacy of dexamethasone to reverse monocrotaline (MCT)-induced pulmonary hypertension and augment atrogin-1 expression in both pulmonary arteries and myocardium. Dexamethasone caused significant reductions in body weight in combination with MCT. As predicted, MCT-induced pulmonary hypertension was evident by increases in RV systolic pressure, right ventricle to left ventricle plus septal weight ratios (RV/LVS) and arterial remodeling. MCT treatment significantly reduced both RV and PA atrogin-1 expression. Dexamethasone treatment reversed the MCT-induced pathological indices and restored RV atrogin-1 expression, but did not impact atrogin-1 expression in pulmonary arteries. Myostatin was poorly expressed in pulmonary arteries compared to the RV, and dexamethasone treatment increase RV myostatin in controls but not MCT-treated rats. These findings suggest that mechanisms independent of myostatin/atrogin-1 are responsible for glucocorticoid efficacy in this model of pulmonary hypertension.

PubMed ID: 22311109 Exiting the NIEHS site

MeSH Terms: Animals; Blood Pressure/drug effects; Blood Pressure/physiology; Dexamethasone/pharmacology*; Disease Models, Animal; Drug Antagonism; Gene Expression*; Glucocorticoids/pharmacology*; Heart Ventricles/drug effects; Heart Ventricles/pathology; Heart Ventricles/physiopathology; Hypertension, Pulmonary/drug therapy*; Hypertension, Pulmonary/metabolism; Hypertension, Pulmonary/physiopathology; Hypertrophy, Right Ventricular/chemically induced; Hypertrophy, Right Ventricular/pathology; Hypertrophy, Right Ventricular/physiopathology; Male; Monocrotaline/toxicity*; Muscle Proteins/genetics*; Muscle Proteins/metabolism; Myostatin/metabolism; Pulmonary Artery/drug effects; Pulmonary Artery/metabolism; Pulmonary Artery/pathology; RNA, Messenger/metabolism; Rats; Rats, Sprague-Dawley; SKP Cullin F-Box Protein Ligases/genetics*; SKP Cullin F-Box Protein Ligases/metabolism

Back
to Top